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Objective. Multiple-dose metronidazole oral therapy is currently the reference treatment for bacterial vaginosis (BV). This double-
blind, double-dummy, noninferiority study compared the eﬃcacy of secnidazole, another nitroimidazole with pharmacokinetics
allowing a single dose regimen, to this standard treatment. Methods. A total of 577 patients were randomized to receive
metronidazole (500mg, b.i.d for seven days) or secnidazole (2g, once). Therapeutic cure at D28 was deﬁned as the resolution
of vaginal discharge, positive KOH whiﬀ test, vaginal pH > 4.5 and Nugent score > 7 on Gram-stained vaginal ﬂuid. Results.
According to this primary endpoint, the single-dose secnidazole regimen was shown to be at least as eﬀective as the multiple-
dose metronidazole regimen (60.1% cured women vs 59.5% , 95% conﬁdence interval with a noninferiority margin of 10%:
[−0.082;0.0094]). Safety proﬁles were comparable in both groups. Conclusion. The secnidazole regimen studied represents an
eﬀective, convenient therapeutic alternative that clinicians should consider in routine practice.
1.Introduction
Bacterial vaginosis (BV) is a common cause of vaginal
discharge, occurring in up to 30% of women [1]. It is
associated with a complex change in vaginal ﬂora including
ad e c r e a s ei nn o r m a lLactobacillus spp., and an increase in
Gardnerella vaginalis and anaerobes [1, 2].
Essentiallycharacterizedbyaﬁshy-smelling,thin,greyish
vaginal discharge [2], BV is clinically diagnosed using the
Amsel criteria, including four parameters: presence of the
typical discharge, a vaginal pH > 4.5, a positive whiﬀ test
(amine odour after adding 10% potassium hydroxide to
vaginal ﬂuid) and the presence of “clue cells” (epithelial
cellswithadhering bacteria)onmicroscopic examination. At
least three out of these four criteria have to be present [2].
The diagnosis may be conﬁrmed by a Nugent score equal
or higher than seven on bacteriological analysis of vaginal
samples.
Besides being unpleasant for patients when symptoms
of discharge and odour occur, BV is associated with an
increased risk of several pathological gynaecological condi-
tions as well as major adverse outcomes during pregnancy.
It is estimated that BV is associated with a twofold increased
risk of preterm birth (odds ratio: 2.4; 95% CI: 1,2–4,8) and a
sixfold increased risk of miscarriage (odds ratio: 6.6; 95% CI:
2.1–20.9) [3].
Although the pathogenesis of BV is still not clearly
understood and the aetiological role played by the organisms
replacingthenormalaerobicvaginalﬂoraremainsuncertain,
antibiotics with good activity against anaerobes but that do
not aﬀect Lactobacillus spp. represent the mainstay of BV
therapy [2]. Metronidazole, administered either orally or
topically according to multiple-dose regimens, has long been
established as a standard treatment of BV [4–6]. However,
a drawback of these regimens is the necessity to administer
them for several days, potentially diminishing compliance2 Infectious Diseases in Obstetrics and Gynecology
with a risk of incomplete cure and recurrence of BV
[7].
Secnidazole is a new second-generation 5-nitroimidazole
product with a broad spectrum of activity against anaerobic
bacteria and a longer half-life than metronidazole, making
it suitable for single-dose therapy, and therefore potentially
oﬀers an advantage over multiple-dose metronidazole regi-
mens. Several studies have consistently suggested its clinical
beneﬁts for the treatment of BV [8–10]. However, their
methodology was somewhat questionable and there was a
need to investigate the eﬃcacy of secnidazole in a well-
designedstudysatisfyingthemostrecentguidelineslikethese
issued by the Food and Drug Administration (FDA).
2.MaterialsandMethods
This was a national, multicentre, prospective, randomised,
comparative, double-blind, double-dummy, Phase III, non-
inferiority study comparing the eﬃcacy of secnidazole
versus metronidazole in patients with bacterial vaginosis.
Nonpregnant women aged 18–65 years with clinical signs
of bacterial vaginosis, and from whom a vaginal sample
had been collected at the preinclusion visit, were eligible
for enrolment. The clinical diagnosis of BV was established
on the basis of the following three Amsel criteria: a
homogeneous,thin,greyish-whitevaginaldischarge,positive
potassium hydroxide whiﬀ test results, and a vaginal pH
above 4.5 [11]. The diagnosis of BV was later conﬁrmed
by a Nugent score above seven on bacteriological analysis
of the preinclusion vaginal samples. Patients were excluded
if they had received antibiotic or antifungal drugs within
the past 14 days. The study was approved by the Ethics
Committee of Kremlin Bicˆ etre Hospital (France) and all
women gave written informed consent before starting the
study.
2.1. Study Design. After baseline screening, patients were
randomised to metronidazole (reference treatment) or sec-
nidazole (study treatment) in a 1:1 ratio. Randomisation
was stratiﬁed by clinical centre; the randomisation list was
computer-generated (SAS software) with block sizes of four
(two secnidazole, two metronidazole). Investigators and
patients were blind to study treatments.
After randomisation, patients received either a single
2g dose of secnidazole or the reference treatment, that is,
a seven-day course of 500mg metronidazole twice daily.
In view of the diﬀerence in pharmaceutical form and
administration regimen between metronidazole (capsules,
multiple-dose) and secnidazole (sachet, single-dose), the
trial was designed as a double-dummy study. According
to the randomisation schedule, patients received either the
study treatment and the placebo of the reference treatment
or the reference treatment and the placebo of the study
medication (one sachet on Day 1, and two capsules per day
from Day 1 to Day 7). The patients attended two followup
visits, at day 14 (D14) ± 2 days and at day 28 (D28) ± 2
days. At each visit, a clinical examination was performed and
vaginal samples were taken.
Table 1: Major deviations leading to the exclusion of patients from
the per protocol population.
Metronidazole Secnidazole
n = 287 n = 290
%( n)% ( n)
Nonrespect of
scheduled visits 4.9 (14) 3.8 (11)
Nonevaluability of
primary eﬃcacy
endpoint
4.5 (13) 1.7 (5)
Concomitant
antibiotic treatment 3.5 (10) 2.1 (6)
Nonrespect of
compliance 2.4 (7) 1.4 (4)
of which missing
data on compliance 1.4 (4) 1.4 (4)
Error in
randomisation 1.4 (4) 1.4 (4)
Treatment initiated
more than 3 days after
randomisation
1.0 (3) 0 (0)
Nonrespect of
inclusion criteria 0.3 (1) 0.7 (2)
Vaginal treatment 0 (0) 0.7 (2)
Nonrespect of
exclusion criteria 0 (0) 0.3 (1)
Table 2: Overall therapeutic success at D28 (primary eﬃcacy
endpoint).
Population
ITT mITT PP
Secnidazole 58.3% 60.1% 63.4%
(169/290) (146/243) (137/216)
Metronidazole 57.8% 59.5% 62.9%
(166/287) (141/237) (127/202)
95% CI Secnidazole-
Metronidazole
[−0.076;
0.085]
[−0.082;
0.094]
[−0.087;
0.098]
NS: not signiﬁcant.
2.2. Endpoints. In accordance with the current FDA guide-
lines, the primary eﬃcacy endpoint was the therapeutic suc-
cess, that is, a composite of clinical and bacteriological cure,
atD28[12].Clinicalcurewasdeﬁnedasthenormalisationof
the three Amsel criteria and bacteriological cure was deﬁned
as a Nugent score lower or equal than three. The secondary
eﬃcacy criteria were therapeutic success at D14, clinical cure
at D14 and D28, bacteriological cure at D14 and D28, mean
time to symptom disappearance, and safety. Patients had to
complete a daily questionnaire from D1 to D14, recording
the intensity of any vaginal discharge (severe, moderate or
absent) and the existence of an unpleasant odour (yes/no).
Safety was assessed on the basis of adverse events reported.
2.3.Populations. Theprimaryeﬃcacyendpointwasanalysed
on the intention-to-treat (ITT) population, including allInfectious Diseases in Obstetrics and Gynecology 3
randomised patients who received at least one dose of the
treatment, on the modiﬁed ITT (mITT) population deﬁned
as all the patients of the ITT population in whom the diag-
nosis of BV was conﬁrmed after bacteriological examination,
and on the per protocol (PP) population comprising all
patients included in the mITT population who completed
the study protocol without any major deviation and were
evaluable at all study visits. The main population was mITT
population, but consistent results between mITT and PP
populations were expected due to the noninferiority design
of the study. Patients not evaluable at D28 were reported
as “therapeutic failures” in the ITT and mITT populations.
Safety analyses were performed on the ITT population.
2.4. Sample Size and Statistical Analysis. The study was
designed with ≥90% power to test the hypothesis that a
single dose of secnidazole is noninferior to a seven-day
course of metronidazole. According to published studies,
the cure rate with the reference treatment was estimated
to be approximately 87% [13]. Assuming this cure rate, a
noninferiority margin ﬁxed at 10% and a similar dropout
rate in the two groups, a sample size of 432 patients (216
per group) was needed to determine noninferiority with a
power of 80% and an alpha error of 2.5% (one-sided test).
Postulating that 25% of recruited patients would not be
evaluable for the primary criteria, the targeted recruitment
was 287 patients per group.
Noninferiority was tested using the conﬁdence interval
(CI)approach:theprimaryandsecondaryeﬃcacyendpoints
were analysed by calculation of the bilateral (two-sided)
95% CI of the diﬀerence in rate “Secnidazole group-
Metronidazole group”. The lower limit of the CI was
compared to the −10% limit of noninferiority. The mean
time to symptom disappearance was compared between the
two groups using the log-rank test. Safety data were analysed
using Chi-square tests (Pearson’s or Fisher’s).
3. Results andDiscussion
3.1. Results. The study was performed between March
2007 and July 2008 at 27 sites in France. A total of 577
women (mean age: 36 years in both groups) were enrolled
and randomised to receive secnidazole (ITT, n = 287) or
metronidazole (ITT, n = 290) (Figure 1). Approximately
28% of patients (secnidazole: 27.2%; metronidazole: 28.6%)
had experienced at least one episode of BV during the two
years preceding inclusion. After bacteriological examination,
the diagnosis of BV was conﬁrmed in 237 patients (81.7%)
in the metronidazole group and 243 patients (84.7%) in the
secnidazole group (mITT population). During the study, 16
premature withdrawals (metronidazole, n = 12; secnidazole,
n = 4; P = .045) were reported, the main reasons cited being
“personal convenience” (metronidazole, n = 4; secnidazole,
n = 3) and “lost to followup” (metronidazole, n = 3). At the
end of the study, major deviations from the protocol, most
frequently nonrespect of scheduled visits, nonevaluability of
the primary eﬃcacy endpoint and concomitant antibiotic
treatment,werereportedfor35subjectsinthemetronidazole
Pre-included
n = 579
Randomised
n = 577
Metronidazole group Secnidazole group
ITT population
n = 287
ITT population
n = 290
mITT population
n = 237
mITT population
n = 243
Per protocol population
n = 202
mITT population
n = 216
Figure 1: Treatment groups and populations.
group and 27 subjects in the secnidazole group (Table 1).
“Nonrespect of compliance” was reported for seven patients
in the metronidazole group and four patients in the secnida-
zole group. Overall, 202 patients in the metronidazole group
and 216 patients in the secnidazole group were included in
the PP population.
3.1.1. Primary Eﬃcacy Endpoint: Therapeutic Success at D28.
In the mITT population, therapeutic success (both clinical
and bacteriological cure) at D28 was achieved in similar per-
centages of patients in both groups: 59.5% (141/237) in the
metronidazolegroupand60.1%(146/243)inthesecnidazole
group (Table 2). The lower limit of the 95% conﬁdence
interval of the diﬀerence “secnidazole-metronidazole” was
above −10% ([−0.082; 0.094]), conﬁrming the noninferior-
ity of secnidazole compared to metronidazole. The rates of
therapeuticsuccessinthePPandITTpopulationsconﬁrmed
thenoninferiorityofsecnidazolecomparedtometronidazole
(Table 2).
3.1.2. Therapeutic Success at D14. At D14, therapeutic
success in the mITT population was observed in 66.2%
(157/237) of patients in the metronidazole group versus 65%
(158/243) of patients in the secnidazole group (Table 3). The
noninferiority of secnidazole was conﬁrmed by the limits of
the 95% CI for the diﬀerence “secnidazole-metronidazole”
(95% CI: [−0.097; 0.073]). In the PP population, the
percentages of patients achieving therapeutic success were
similar in the two treatment groups (Table 3), corroborating
the noninferiority of secnidazole. In the ITT population,
the lower limit of the 95% CI was slightly below −10%,
but the diﬀerence between the groups was not statistically
signiﬁcant.
3.1.3. Clinical and Bacteriological Cures Assessed Separately.
At D28, clinical cure was achieved in 77% of patients in
the secnidazole group and bacteriological cure in 70.3%,
higherpercentagesthanthetherapeuticsuccessrate(≈60%),4 Infectious Diseases in Obstetrics and Gynecology
Table 3: Overall therapeutic success at D14.
Population
ITT mITT PPD14∗
Secnidazole
62.4% 65.0% 68.7%
(191/290) (158/243) (147/214)
Metronidazole
65.2% 66.2% 69.0%
(187/287) (157/237) (149/216)
95% CI
Secnidazole-Metronidazole
[−0.106; 0.051] [−0.097; 0.073] [−0.09; 0.085]
∗PPD14 (per protocol population at day 14): patients who were assessable and presented no major deviation from the protocol at day 14 (214 patients in the
metronidazole group and 216 patients in the secnidazole group).
Table 4: Clinical and bacteriological cures at D14 and D28 in the mITT population.
Clinical cure (%) Bacteriological cure (%)
D14 D28 D14 D28
Secnidazole 79.7% 77% 77.5% 70.3%
(n = 243) (n = 193) (n = 187) (n = 188) (n = 171)
Metronidazole 77.9% 79.3% 77.3% 71.4%
(n = 237) (n = 145) (n = 188) (n = 183) (n = 169)
95% CI Secnidazole-
Metronidazole [−0.056; 0.093] [−0.098; 0.052] [−0.073; 0.079] [−0.093; 0.072]
NS: not signiﬁcant.
as some patients achieved clinical cure but not bacterio-
logical cure and vice versa. Similar results were obtained
with metronidazole (Table 4). Considering clinical cure not
only with bacteriological cure but also with bacteriological
improvement (Nugent score between three and seven),
the percentage of responding patients increased to around
70% in both groups (Table 5). Analysis of the PP and
ITT populations gave similar results, with little diﬀerence
between the secnidazole and metronidazole groups (data not
shown).
3.1.4. Mean Time to Symptom Disappearance. Among the
patients of the mITT population completing the self-
assessment diary, more than three-quarters reported the
disappearance of BV symptoms, within a mean of 7.12 days
in the metronidazole group and 6.83 days in the secnidazole
group (Table 6). Similar results were observed in the PP and
ITT populations (data not shown).
3.1.5. Safety. Safety was evaluated in all randomised patients
who took at least one dose of the study treatment. In
the two treatment groups, a similar proportion of patients
experienced at least one adverse event (AE): 109 (38%) in
the metronidazole group and 113 (39%) in the secnidazole
group. No diﬀerences were observed in the frequencies
of AE classiﬁed by Organ System, with the exception of
headaches, more frequent, although rare, in the secnidazole
group (n = 10 versus n = 4 in the metronidazole group).
The diﬀerence in the rate of patients reporting an expected
AE between the metronidazole group (n = 27, 9.4%) and
the secnidazole group (n = 16, 5.5%) was at the limit of
statistical signiﬁcance testing. The percentages of subjects
reporting at least one drug-related AE were similar in the
two treatment groups: 22.7% (n = 65) in the metronidazole
group and 22.4% (n = 65) in the secnidazole group, most of
theseAEbeingmildinintensity(66.2%inthemetronidazole
group and 67.7% in the secnidazole group) and associated
with complete recovery by the end of the followup period
(28 days) (49.2% of patients in the metronidazole group
and 53.9% of patients in the secnidazole group). The most
frequent unresolved events (vaginitis and abnormal genital
discharge) could be considered as treatment failure.
3.2. Discussion. This large, randomised, double-blind,
double-dummy Phase III clinical trial designed according to
the most recent FDA guidance [12] conﬁrmed the eﬃcacy
and safety of a single-dose regimen of secnidazole compared
to the standard multiple-dose metronidazole regimen.
In all patient populations (ITT, mITT, and PP), around
60% of patients in both treatment groups achieved both
bacteriological and clinical cure at D28. The time to
symptom disappearance was also similar in both groups.
The observed therapeutic success rate was lower than those
reported in previous trials investigating oral metronidazole
in this indication. In a systematic review of metronidazole
treatment of BV published in 1992, the four studies eval-
uating metronidazole 500mg bid for seven days reported
an initial cure rate within four weeks ranging between 83%
and 97% [13]. The recently published Cochrane Review
assessing the eﬀectiveness of antimicrobial agents used to
treatBVinnonpregnantwomen,excludedthesefourstudies,
as the methods used for BV diagnosis were deemed doubtful,
but selected seven other similar trials, mostly performed inInfectious Diseases in Obstetrics and Gynecology 5
Table 5: Clinical cure with bacteriological improvement and/or cure at D14 and D28 in the mITT population.
Therapeutic success (%) Clinical cure with bacteriological cure
(i.e., clinical and bacteriological cure) or improvement∗ (%)
D14 D28 D14 D28
Secnidazole 65.0% 60.1% 72% 69%
(n = 243) (158/243) (146/243) (n = 174) (n = 167)
Metronidazole 66.2% 59.5% 72% 67%
(n = 237) (157/237) (141/237) (n = 171) (n = 158)
95% CI Secnidazole-Metronidazole [−0.097; 0.073] [−0.082; 0.094]
∗Bacteriological improvement deﬁned as a nugent score between 3 and 7.
Table 6: Mean time to symptom disappearance in the mITT population.
Patients completing the Patients reporting Time to symptom disappearance
questionnaire symptom disappearance (no. of days)
%( n)% ( n) Mean ± SD Median ± SD
Secnidazole 84.4% 82.4% 6.83 ±0.24∗ 6
(n = 243) (205) (169)
Metronidazole (n = 237) 86.9% (206) 79.6% (164) 7.12 ±0.25∗ 7
∗Diﬀerence between treatment groups not statistically signiﬁcant.
the late 1980s and early 1990s [2, 14–20]. Once again, the
cure rates reported, ranging between 78% and 96%, were
substantially higher than that recorded in our study (60%).
Several explanations may be postulated for this discrep-
ancy. Firstly, whereas in our study, diagnosis and cure were
deﬁned according to the stringent deﬁnitions given in the
FDA guidance [12] taking into account both bacteriological
and clinical criteria, most previous studies used less rigorous
endpoints often based on clinical criteria only. Interestingly,
the clinical cure rate achieved at D28 (secondary endpoint)
in our metronidazole group of patients (77%) is close to the
ratesreportedinthesepreviousstudies.Secondly,theseolder
studies, some being open-label, included fewer patients.
Finally, therapeutic cure was sometimes assessed after too
short a time posttreatment, and this is a crucial limitation
since evaluation of BV before one month of treatment is
known to be inaccurate [21].
Considering only the two previous randomised, double-
blind, controlled studies including at least 100 patients,
“clinical cure rates” reported at D28 after treatment with
metronidazole were lower [17, 19]. Both these studies com-
pared oral metronidazole (500mg twice a day for seven days)
versus vaginal clindamycin in approximately 400 patients.
I no n es t u d y ,c u r eo fB Vd e ﬁ n e da sap H≤ 4.5, absence
of amine odour after addition of potassium hydroxide, and
absence of clue cells, was observed in 54% of patients in the
metronidazole group at one month posttherapy [17]. Cure
or improvement (requiring two of the criteria deﬁning cure)
was achieved by 78% of patients. In the other study, the
overall cure rate determined on the basis of the absence of
cluecellsandofanamineodourreached76.3%atthesecond
followup visit scheduled between 28 and 42 days after the
start of treatment [19]. Interestingly, these rates are of the
same order of magnitude as the clinical cure rate achieved
at D28 (secondary endpoint) in our metronidazole group:
77%.
Similarly, a recent review recalculating the four-week
cure rate for oral metronidazole based on the results of
published placebo-controlled studies, quoted an anticipated
a v e r a g ec u r er a t eo f6 6 % ,w h i c hi si na c c o r d a n c ew i t ho u r
therapeutic success rate [22].
In the previous studies assessing the eﬃcacy of a single
oral 2g dose of secnidazole for the treatment of BV,
the reported cure rates (72% and 93%) were also higher
than the therapeutic success rate observed at D28 in our
secnidazole-treated patients (≈60%), probably for the same
methodological reasons [8, 10].
Thesecondaryendpointanalysisshowedthattherapeutic
success rates at D14 were slightly superior to those observed
at D28, both in the secnidazole group (62.4% versus 58.3%)
and in the metronidazole group (65.2% versus 57.8%),
testifying either relapse or recurrence, probably due to the
persistence of the original imbalance in vaginal ﬂora. The
diﬀerence in success rates at D14 and D28 observed was
of the same order within each treatment group. Available
data indicate that when BV reappears, it is more likely to
represent reactivation rather than a new infection [22]. This
result highlights the relevance of assessing treatment eﬃcacy
at D28, as recommended in the FDA guidelines.
Secnidazole has been extensively used for the past
20 years to treat various parasitic diseases, including tri-
chomoniasis, and its good safety proﬁle is well established.
Neither the preclinical toxicity studies nor the accumulated
postmarketing experience in its approved indications gave
evidence of a risk of adverse events with secnidazole during
pregnancy. This study conﬁrmed that secnidazole is well-
tolerated, adverse events recorded being mild in severity and
predominantly those known to be associated with imidazole6 Infectious Diseases in Obstetrics and Gynecology
derivatives as a whole. The relationship of adverse events
to secnidazole was diﬃcult to evaluate in this study, as the
occurrence of adverse events was evaluated three weeks after
the administration of a single dose of the drug.
4. Conclusion
In conclusion, these results are important to the extent that
this randomised, double-blind, double-dummy clinical trial
is the ﬁrst one to assess the eﬃcacy of the reference treatment
with oral metronidazole in a large population of patients
with BV following a rigorous methodology which conforms
to the recent FDA guidance. Secnidazole was at least as
eﬀective as metronidazole with a similar favourable safety
proﬁle. With its more convenient posology, that is, a single-
dose regimen versus a twice-a-day regimen for seven days
with the reference drug, secnidazole represents an attractive
therapeutic option that should be considered in routine
practice, particularly in women whose likely compliance is
doubtful or in women who are asymptomatic and question
the necessity of a treatment over several days [22].
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